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1. Introduction 
Charcot neuro-osteoarthropathy (CNO) is a disabling, rapidly progressive destructive 
arthropathy and a devastating condition in patients with sensitive neuropathy secondary to 
different diseases such as diabetes mellitus, syringomyelia, polyomielitis, multiple sclerosis 
or leprosy (Storey, 2004). Diabetes is nowadays the most common cause of 
neuroarthropathy, with the joints of foot being most frequently affected (Shae & Boulton, 
1995). The reported incidence and prevalence of CNO varies between 0,1-0,4% of diabetic 
population, but the real prevalence of CNO in patients with diabetes mellitus is unknown 
because many cases are undiagnosed due to a lack of recognition of the clinical symptoms of 
acute presentation (Bailer & Root, 1947;  Fabrin et al., 2000; Klenerman, 1996; Rajbhandari et 
al., 2002; Sinha et al., 1972). Both type 1 and type 2 diabetic patients are at risk. The majority 
of patients with CNO are between the fifth and sixth decades although type 1 diabetes 
present CNO at a younger age and most patients have had diabetes for at least 10 years 
(Clouse et al., 1974; Cofield et al., 1983; Petrova et al., 2004). Bilateral involvement has been 
described in up to 30% of patients with CNO affecting the feet (Shae & Boulton, 1995). The 
basic physiopathologic mechanism of CNO is poorly understood although repetitive trauma 
and autonomic nervous dysfunction are probably implicated (the neurotraumatic and 
neurovascular theories). Probably there is a triggering factor including trauma or infection 
which triggers the onset of an inflammatory cascade which leads to an increased osteoclastic 
activity in some predisposed patients.  
Although there is no clear evidence, the RANK/RANKL/OPG system may play an 
important role in the osteolysis seen in the acute CNO. The initial trigger leads to a 
production of proinflammatory cytokines, including tumor necrosis factor alpha (TNF) 
and interleukin-1(IL-1). The expression of these cytokines could increase the expression of 
receptor activator of nuclear factor-B (RANKL), the ligand of receptor activator of NF-kB 
(RANK), that when activated, stimulates the production of nuclear transcription factor NF-
kB (NF-kB). When NF-kB is expressed in osteoclast precursors cells, it leads to their 
differentiation to mature osteoclasts and, in consequence, bone resorption (Jeffcoate et al., 
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2005; Jeffcoate, 2008; Molines et al., 2010). In this sense, Mabilleau et al. studied isolated 
peripheral blood monocytes from diabetic Charcot patients, diabetic controls and healthy 
controls and demonstrated that resorption in acute CNO is related to an increase in RANKL-
mediated osteoclastic activity (Mabilleau et al., 2008).  
The usual initial presentation of acute CNO is a swelling, tender and warm involved joint 
and there is usually a temperature difference greater than 2ºC when compared with the 
contralateral joint (Jude & Boulton, 2001; Petrova & Edmonds, 2008). The whole clinical 
picture can simulate an infection in its appearance. The chronic CNO is painless, without a 
temperature difference and characterized by established deformity. 
The aim of this chapter is to review the usefulness of biochemical bone markers and the 
image features for both diagnosis and for follow-up after treatment of CNO with 
bisphosphonates (pamidronate).  
2. Imaging and biochemical markers of turnover in diagnosis of Charcot 
neuro-osteoarthropathy 
Although the diagnostic is based on clinical findings, conventional radiography, 
radionucleide scintigraphy and magnetic resonance imaging (MRI) are the more common 
modalities used for helping to the diagnosis of CNO.  
2.1 Plain radiography 
X-plain radiographs are usually the first exam used and they are useful for anatomical 
information. However they are neither sensitive nor specific to differentiate acute CNO 
changes from osteomyelitis.  
In early stages, the presence of effusion with minimal subluxation and fracture-bone 
fragmentation should alert to the physician to the possibility of CNO. These initial changes 
may progress to collapse, resorption and subchondral bone fragmentation, bone 
proliferation with sclerosis and osteophytosis, intra-articular bone fragments, complete 
subluxation, massive soft tissue enlargement and effusion and fracture of neighboring bones 
(Resnick & Niwayama).  
The Eichenholtz classification (Eichenholtz, 1966) modified by Shibata et al. (Shibata et al., 
1990) describe a correlation between clinical findings and radiographic features (table 1). 
 
Stage 0 early phase acute symptoms no changes 
Stage 1 development 
stage 
acute symptoms osteopenia, bone destruction, debris 
formation, 
fragmentation of the subchondral bone ,  
capsular distention, subluxations 
,dislocations 
Stage 2 coalescence 
stage 
decreased symptoms resorption of debris, bony sclerosis ,  
fusion of bone fragments 
Stage 3  reconstruction 
stage 
resolved bony remodeling, rounding of fragments 
Table 1. Eichenholtz classification modified by Shibata. 
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Medical literature focused on radiology findings describe two patterns of CNO: a 
hypertrophic pattern characterized by joint destruction and bone fragmentation, debris 
formation, sclerosis and osteophytosis, such as osteoarthritis and an atrophic pattern 
showing osseous resorption and joint disorganization that may appear similar to septic 
arthritis, so, differential diagnosis between atrophic CNO and septic arthritis may be 
difficult. Frequently, patients present a combination of hypertrophic and atrophic patterns 
(Aliadabi et al., 2003; Jones et al., 2000). 
In the diabetic population, destructive or resorptive bony abnormalities can predominate 
depending on the location of CNO. At the mid-foot or tarsometatarsal joints (Lisfranc) [the 
most common localization representing about 60%(Brodsky)], bone fragmentation, sclerosis 
with fracture-dislocation and complete disintegration of one or more tarsal bone are 
frequently found. This may lead to a collapse of the longitudinal arch and increased load 
bearing on the cuboid, resulting in a “rocker-bottom” deformity. If the metatarsophalangeal 
joints are affected, bone resorption is the predominant feature, leading to a disappearance, 
partial or complete, of the metatarsal heads and proximal phalanges. Finally, the hindfoot 
and ankle, although less frequent, it may be affected with fragmentation, eburnation and 
dislocation of the affected bones.  
In summary, the five D’s describe the radiological features of CNO: joint distension, 
dislocations, debris, disorganization and increased density (Rajbhandari et al., 2002), being 
the presence of multiples fractures the most suggestive radiologic pattern of CNO. 
2.2 Radionucleide scintigraphy 
Three imaging phases 99Technetium bone scan (99Tc-scan) are highly sensitive (91%) for osseus 
pathology but lacks specificity (54%) for the diagnosis of CNO (Aliadabi et al., 2003; Sella, 
2009; Schauwecker et al., 1988). The scintigraphy is positive in all 3 phases, reflecting an 
increased bone turnover, a similar situation to that found in other conditions such as 
osteomyelitis. In these cases, in order to improve the specificity of the test to rule out infection 
the labeled white cell scans (99Tc-WBC, HMPAO, 111In-WBC) can be used. These scintigraphy 
techniques show increased activity at the site of infection, reaching a specificity of 60-86% 
depending on the studies and on the radiotracer used to label white cells (Sella, 2009).  
A fourth phase or 24-hour phase image 99Tc-scan can be used to improve the localization of 
the affected site when there is too much background activity. 
The 67Ga/bone imaging study is not reliable for diagnosing osteomyelitis because 67Ga also 
accumulates in sterile CNO (Glynn, 1981; Knight et al. 1988). 
Given its high sensitivity, the scintigraphy may be useful in early diagnosis although can 
not rule out the presence of a coexisting infection. However it has two major limitations: 
sometimes may not differentiate bone infection from that of adjacent soft tissues due to low 
resolution, and the presence of peripheral ischemia can limit sensitivity.  
2.3 Magnetic resonance imaging  
The role of MRI for diagnostic imaging of the diabetic foot is increasing due to its 
advantages over scintigraphy and radiographs but its use is still unclear.The T1-weighted 
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sequences show anatomical references, both normal or abnormal, while T2- and STIR- (short 
tau inversion recovery) weighted sequences are better to demonstrate edema and 
inflammatory changes in the soft tissues and bone.  
Some possible algorithms have been proposed (Giurato & Uccioli, 2006) but it is usually 
considered that MRI is not necessary in patients with evidence of CNO on plain radiographs 
and no clinical signs of infection (Giurato & Uccioli, 2006; Marcus et al., 1996). 
CNO may present with two types of changes on MRI, depending on the evolution time of 
the process. Acute CNO shows a low signal intensity within bone marrow on T1-weighted 
sequences and high signal intensity on T2- and STIR-weighted sequences, findings that are 
similar to those observed in osteomyelitis. In a chronic CNO, besides cortical fragmentation, 
joint deformity and dislocation, typically appears a low signal intensity in the bone marrow 
on both T1- and T2-weighted sequences consistent with osteosclerosis on plain radiography. 
Another finding in chronic CNO is cyst-like lesions in the bone marrow which appear as 
well-defined clearly marginated low signal lesions on T1-weighted images and as high 
signal intensity on T2-weighted images (Beltran et al. 1990; Marcus et al., 1996).  
MRI may also be useful to early diagnosis when patients present acute symptoms and no 
changes in plain radiographs can be detected (stage 0 of Eichenholtz classification). In these 
cases, MRI may detect early events, such as bone edema, occult fractures and joint effusion 
(Chantelau & Poll, 2006; Edmonds et al., 2006; Greenstein et al., 2002).  
Bone and soft tissue infection involving the foot is particularly common in patients with 
diabetes mellitus, and in these patients, CNO often coexists. The differentiation between 
these two entities is difficult. There are some MRI features that help to differentiate acute 
CNO from osteomyelitis: bone marrow signal damage and edema pattern, distribution of 
the changes, presence of deformity and soft tissue changes (ulcers, abscess or sinus tracts) 
(Lederman & Morrison, 2005; Lederman et al., 2002; Tan & Teh, 2007). Ahmadi et al., in a 
retrospective review of contrast-enhanced MRI study of 128 neuropathic feet joints in 63 
diabetic patients with a suspicion of osteomyelitis, found that the presence of sinus tract, 
the presence of soft-tissue fluid collection and extensive bone marrow abnormality  
were MRI features commonly present in a superimposed infection (Ahmadi et al., 2006) 
(table 2). 
Several studies demonstrate that MRI has a high sensitivity (77-100%) and specificity (80-
100%) for osteomyelitis. Furthermore, in osteomyelitis MRI has a positive predictive power 
of 93% and almost a negative predictive power of 100% according to studies that compared 
MRI results to bone biopsy, which is considered the gold standard for diagnosing 
osteomyelitis (Levine et al., 1994; Marcus et al., 1996). However there are no studies 
assessing neither the sensitivity nor specificity of MRI detecting osteomyelitis in CNO 
patients.  
The use of gadolinium in CNO is controversial (Marcus et al.,1996; Morrison et al., 1993)  
although may be useful to complete the soft tissue study (abscesses, sinus tracts, cellulitis). 
In summary, MRI is a useful, non-invasive tool for the early diagnosis of CNO and may 
have utility for detecting a superimposed infection, being the soft tissue alteration the most 
specific finding.  
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 Osteomyelitis Charcot Neuro-osteoarthropathy 
 Bone features
Bone 
marrow 
Low intensity T1-
High intensity T2-  
and STIR- 
Acute CNO Chronic CNO 
 Low intensity T1-
High intensity T2-  
and STIR-
Low intensity T1- 
Low intensity T2- 
and STIR- 
 Diffuse edema Periarticular and subcondral edema 
Distribution Focal bone involvement Several bone affected
 Weight bearing regions Predominant midfoot involvement 
Deformity Not common Common
 Soft tissue features
 Frequently involved: sinus tracts, 
cellulitis, abscess
Infrequently  involved
Table 2. Differential MRI patterns between osteomyelitis and Charcot neuro-
osteoarthropathy. 
2.4 Biochemical markers of bone turnover 
Biochemical markers of bone turnover are often altered in CNO. There are few studies done, 
most of them evaluating the changes of these markers after treatment, mainly 
bisphosphonates. Some studies on bone turnover markers show an increase of these 
parameters in acute CNO, indicating an unspecific increased in bone activity. Gough et al. 
measured the pyridoline cross-linked carboxy-terminal telopeptide domain of type 1 
collagen (1CTP) and carboxy-terminal propeptide of type 1 collagen (P1CP), both validated 
as markers of bone resorption and formation respectively, in diabetic patients with acute 
CNO, chronic CNO, diabetic controls and non-diabetic controls subjects (Gough et al., 1997). 
Serum 1CTP was significantly raised in the dorsal venous arch of the acute CNO feet 
compared to chronic CNO, diabetic controls and non-diabetic controls. The authors did not 
find any significant difference in serum P1CP levels in any group. These levels of 1CTP and 
P1CP suggest an increase in osteoclastic activity without concomitant increase of 
osteoblastic function. Selby et al. found an increase in bone-specific alkaline phosphatase 
(bone formation marker) with no significant changes among the others biochemical 
parameters studied: osteocalcin, urinary hydroxyproline, urinary desoxypyridinoline ( Selby 
et al., 1998). Increased levels of urinary cross-linked N-telopeptides of type 1 collagen (NTX) 
have been also demonstrated in CNO patients (Edelson et al., 1996).  
In summary, there are few studies focused on bone markers in CNO. The data suggest an 
increase of them in acute CNO especially of resorption parameters. However, it seems that 
the role of bone markers for the diagnosis is yet to be determined.  
3. Imaging and biochemical markers of bone turnover after medical treatment 
of Charcot neuro-osteoarthropathy 
Although the cornerstone of treatment of CNO is immobilization, there are some studies 
that demonstrate the clinical benefit of bisphosphonates. The improvement with 
bisphosphonates appears to be sooner compared to patients with conventional therapy 
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(immobilization) (Anderson et al., 2004). Most studies use pamidronate, although 
alendronate has been demonstrated to be useful in one study (Pitocco et al., 2005). The 
optimal treatment regimen of pamidronate remains to be defined. Multiples observational 
studies have been published using different doses and duration, and all of them have 
demonstrated some clinical improvement (Navqi et al., 2008; Selby et al., 1994; Young, 1999). 
Furthermore, some reports have also shown an improvement in radiological changes (Guis 
et al., 1999) and/or decrease of biochemical bone turnover markers. 
Jude et al. published the first trial of pharmacologic treatment, a randomized, double-
blinded, placebo-controlled study in 39 active CNO patients (Jude et al., 2001). Twenty-one 
patients recieved a single infusion of 90 mg of pamidronate and this group showed a 
significantly reduction in all biochemical markers analized (bone-specific alkaline 
phosphatase (BSAP) and urine deoxypyridoline cross-linked (D-pyr)) that persisted until 24 
weeks in the case of BSAP. However, after 12 months follow-up, both biomarkers rose 
toward baseline levels.  
Comparable results were obtained in 11 patients during treatment with alendronate 70 mg 
once a week over 6 months, in a randomized controlled double blind study. A clinical 
improvement was observed and, 1CTP and urinary hydroxyproline levels, as indicators of 
bone resorption, showed a significant decrease in the treated group after treatment (Pitocco 
et al., 2005).  
Some case reports have demonstrated healing or stabilization of changes on plain 
radiography after intravenous pamidronate (Guis et al., 1999; Naqvi et al., 2008; Young, 
1999).  
In a short communication, Mc Gill et al. reported that bone uptake scintigraphy and skin 
temperature improved over 12 months with immobilization (McGill et al., 2000), but there 
are no studies evaluating changes in neither MRI nor bone scintigraphy after 
bisphosphonate treatment.  
Bem and collages determined quantitative bone scan parameters (ratio of foot and whole-
body uptake and blood flow velocity) and markers of bone turnover (1CTP and BSAP) in 42 
CNO patients (21 with acute and 21 with non-acute CNO) (Bem et al., 2010). The authors 
observed that there was a significant correlation between bone scintigraphy parameters and 
bone turnover markers. In addition, in acute CNO, there was a significant reduction of both 
scintigraphy parameters and levels of 1CTP and BSAP after treatment with calcitonin.  
Schlossbauer and col. published the first report on quantitative assessment of signal 
alterations on constrast-enhanced MRI in CNO stage 0, before and after treatment with 
pressure-relieving means (Schlossbauer et al., 2008). In this study they analyzed the clinical 
symptoms of 13 patients with acute CNO and compared with MRI findings at baseline and 
after 4-month follow-up. They found a significant correlation between bone marrow edema 
and soft tissue edema and pain, with a significant decrease of these parameters after 
treatment. Thus, they concluded that MRI in early stage of CNO provides valuable 
information on the activity of the disease.  
Our group published an open, prospective therapeutical study with a 12-month follow-up 
including 7 consecutive patients (four diabetic, two with syringomielia and one with an 
autonomic neuropathy) with active CNO seen over a period of 3 years (Moreno et al., 2007). 
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Patients included in this protocol received three intravenous infusions of pamidronate at 0, 2 
and 4 months and traditional immobilization methods. Two diabetic patients had a 
concomitant septic arthritis in the affected joint and they received also antibiotic treatment. 
Biochemical markers of bone remodeling, radiological exam and 99Tc-scan were performed 
before and after 12 months treatment. The bone remodeling markers study included blood 
alkaline phosphatase (ALP) and BSAP, urinary crosslinks NTX, pyridoline (pyr) and D-pyr. 
Clinical symptoms improved after the first infusion. Although in most cases the bone basal 
remodeling markers were within normal range values, a clear decrease in almost all of these 
remodeling markers was observed after treatment in all patients, reaching statistical 
significance for NTX and urinary pyr, suggesting that the blocking of the osteoclastic 
activity may play an important role in the physiopathology of CNO, as observed in previous 
studies. All patients, except one with a siringomyelia, showed signs of radiological healing 
with a marked sclerosis and reconstruction of the cortical bone (figure 1). In one case 
pamidronate was administered very early, avoiding the progression and preventing the 
occurrence of radiological changes during the follow-up period (figure 2). Quantitative 
scintigraphy was performed only in 3 cases, showing a decrease in radiotracer uptake after 
treatment although it did not become completely normal. In agreement with previous 
studies, pamidronate improved not only clinical signs but also stopped the progression of 
disease in most cases. 
 
Fig. 1. Patient with a Charcot foot and concomitant septic arthritis. Note before pamidronate 
treatment the presence of bone fragmentation, subluxation, loss of defined contours and 
eburnation and after 6-months treatment sclerosis and defined contours.  
Before treatment After treatment 
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Fig. 2. Patient with a known CNO secondary to syringomielia involving 1st right MCP 
(arrow). She developed a 3rd MCP swelling joint, early detected with scintigraphy. Initial 
radiography did not show any changes. Treatment was administered very early avoiding 
established deformities. 
4. Conclusions 
 early diagnosis in CNO is difficult and needs a high index of suspicion 
Before treatment After treatment 
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 99Tc bone scan scintigraphy and MRI are useful in order to establish early diagnosis 
 99Tc bone scan scintigraphy and MRI can help to detect superimposed infection, a 
condition quite common in diabetic patients   
 biomarkers of bone turnover are increased in acute phase, especially resorptive ones. 
However, their utility for monitoring treatment response remains to be established  
 bisphosphonate treatment appears to be effective not only for clinical improvement but 
also for disease outcome  
 early diagnosis and treatment may be important to avoid late structural damage 
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